SCHEMBL6407880

SCHEMBL6407880

CCCCCc1nc(CCC(=O)O)no1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 4/20 0.46
CDC25A P30304 6/20 0.45
CDC25B P30305 6/20 0.45
CDC25C P30307 5/20 0.45
ALDH1A1 P00352 2/20 0.44
SCD O00767 1/20 0.42
MITF O75030 1/20 0.42
TP53 P04637 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42
ITGB3 P05106 1/20 0.41
ITGAV P06756 1/20 0.41
ITGA2B P08514 1/20 0.41
AKR1B1 P15121 1/20 0.41
LMNA P02545 1/20 0.41
ATM Q13315 1/20 0.41
TSHR P16473 3/20 0.40
PPARG P37231 3/20 0.40
PPARD Q03181 3/20 0.40
GPR84 Q9NQS5 2/20 0.40
HDAC11 Q96DB2 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7955708 0.94 PPARA (0.46) PPARACDC25ACDC25BCDC25CALDH1A1
SCHEMBL7953979 0.92 ALDH1A1 (0.50) PPARAALDH1A1SCDITGB3ITGAV
SCHEMBL7953996 0.83 ALDH1A1 (0.44) PPARAALDH1A1SCDHSD17B10
SCHEMBL20020301 0.81 ALDH1A1 (0.42) PPARAALDH1A1MITFTP53NCOA3
SCHEMBL25252650 0.77 CHRM2 (0.39) PPARA
SCHEMBL3037891 0.76 PPARA (0.41) PPARATDP1
SCHEMBL3264450 0.76 PPARA (0.41) PPARAALDH1A1
SCHEMBL11696814 0.75 PPARA (0.43) PPARAATMTDP1MEN1KMT2A
SCHEMBL25209625 0.75 CHRM2 (0.43) PPARA
SCHEMBL11340693 0.74 CHRM2 (0.41) PPARAGPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1423120-A4 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORP (US) 2005-12-28 EP disclosed
US-6924284-B2 PARP inhibitors ICOS CORPORATION (US) 2005-08-02 US disclosed
EP-1423120-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2004-06-02 EP disclosed
US-20040087588-A1 Parp inhibitors ICOS CORPORATION 2004-05-06 US disclosed
WO-2003015785-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087588-A1 Parp inhibitors PARP1, PARP2, PARP11 PPARA 1279/4885CDC25A 249/4885CDC25B 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.